- Home
- ABUS
as 05-16-2025 4:00pm EST
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WARMINSTER |
| Market Cap: | 672.1M | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 827.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.63 - $4.72 | Next Earning Date: | 05-14-2025 |
| Revenue: | $6,403,000 | Revenue Growth: | -50.69% |
| Revenue Growth (this year): | 14.57% | Revenue Growth (next year): | 15.84% |
Latest Arbutus Biopharma Corporation News
ABUS Breaking Stock News: Dive into ABUS Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
6 days ago
Arbutus: Q1 Earnings Snapshot
GlobeNewswire
6 days ago
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Zacks
6 days ago
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
GlobeNewswire
13 days ago
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
Zacks
24 days ago
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Zacks
25 days ago
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
GlobeNewswire
a month ago
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Compare ABUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABUS Arbutus Biopharma Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.